Association of patient-reported psoriasis severity with income and employment - 19/08/11
, Kathleen M. Fox, PhD b, Vaishali Patel, PharmD, MS c, Chiun-Fang Chiou, PhD c, Frank Dann, MD c, Mark Lebwohl, MD d
Reprint requests: National Psoriasis Foundation, 6600 SW 92 Ave, Suite 300, Portland, OR 97223-7195.Abstract |
Objective |
We sought to examine whether psoriasis severity was associated with patient income and employment.
Methods |
Respondents (>30 years old) to National Psoriasis Foundation surveys (2003-2005) were classified by reported body surface area as having mild (<3%), moderate (3%-10%), or severe (>10%) psoriasis. The relationship between severity and household income (<$30,000 vs ≥$30,000) and employment was assessed by logistic regression, adjusting for age, age at onset, sex, race, and drug treatment.
Results |
Probability of low income (<$30,000) was significantly greater among patients with severe disease than those with mild disease (P = .0002). Patients with severe disease had lower probability of working full time compared with patients with mild psoriasis but it was not statistically significant. Significantly more patients with severe psoriasis (17%) versus mild (6%) reported that psoriasis was the reason for not working (P = .01).
Limitations |
Household income was self-reported and may be influenced by household composition, which is unknown. Psoriasis severity was patient reported and not physician assessed.
Conclusions |
This study demonstrated that income and employment were negatively impacted among patients with severe psoriasis compared with mild psoriasis.
Le texte complet de cet article est disponible en PDF.Plan
| Supported in part by Amgen Inc. |
|
| Disclosure: Dr Fox is a paid consultant to Amgen Inc. Drs Patel, Chiou, and Dann are employees of Amgen Inc. Dr Lebwohl has been a consultant and/or speaker for Amgen, Abbott, Astellas, Centocor, Genentech, Connetics, Pharmaderm, Novartis, Warner Chilcott, and Galderma Laboratories. At the time of this work, Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen Inc, Wyeth, Barrier Therapeutics, Biogen Idec, Centocor, Connetics Corp, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Photomedex, UVBiotek, Valeant Pharmaceuticals, and Warner Chilcott. |
|
| Presented in abstract and poster form at the Annual Meeting of the American Academy of Dermatology in Washington, DC, on February 3, 2007. |
Vol 57 - N° 6
P. 963-971 - décembre 2007 Retour au numéro
Article précédent
- Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
- Elizabeth J. Horn, Kathleen M. Fox, Vaishali Patel, Chiun-Fang Chiou, Frank Dann, Mark Lebwohl
- Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments
- Jeff Hick, Steven R. Feldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?